These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23190248)

  • 1. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality?
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI
    J Gastroenterol Hepatol; 2013 Feb; 28(2):348-56. PubMed ID: 23190248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma.
    Limquiaco JL; Wong GL; Wong VW; Lai PB; Chan HL
    J Gastroenterol Hepatol; 2009 Jan; 24(1):63-9. PubMed ID: 19054256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Lin HC; Huang YH; Wu JC; Chiang JH; Lee PC; Lee SD
    Cancer; 2006 Jul; 107(1):141-8. PubMed ID: 16708358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.
    Hsu CY; Huang YH; Hsia CY; Su CW; Lin HC; Loong CC; Chiou YY; Chiang JH; Lee PC; Huo TI; Lee SD
    J Hepatol; 2010 Jul; 53(1):108-17. PubMed ID: 20451283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey.
    Huo TI; Lin HC; Hsia CY; Wu JC; Lee PC; Chi CW; Lee SD
    Am J Gastroenterol; 2007 Sep; 102(9):1920-30. PubMed ID: 17573792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma.
    Huo TI; Hsu CY; Huang YH; Hsia CY; Lin HC; Lee PC; Loong CC; Chiang JH; Chiou YY; Lee SD
    Liver Int; 2010 Feb; 30(2):198-207. PubMed ID: 19849777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems.
    Huo TI; Hsia CY; Huang YH; Lin HC; Lee PC; Lui WY; Chiang JH; Chiou YY; Loong CC; Lee SD
    J Clin Gastroenterol; 2009 Sep; 43(8):773-81. PubMed ID: 19262404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma.
    Omagari K; Honda S; Kadokawa Y; Isomoto H; Takeshima F; Hayashida K; Mizuta Y; Murata I; Kohno S
    J Gastroenterol Hepatol; 2004 Jul; 19(7):805-11. PubMed ID: 15209629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study.
    Hwang JC; Weng SF; Weng RH
    Jpn J Clin Oncol; 2012 Sep; 42(9):780-6. PubMed ID: 22782961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
    Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
    Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.
    Huang YH; Chen CH; Chang TT; Chen SC; Wang SY; Lee HS; Lin PW; Huang GT; Sheu JC; Tsai HM; Lee PC; Chau GY; Lui WY; Lee SD; Wu JC
    J Gastroenterol Hepatol; 2005 May; 20(5):765-71. PubMed ID: 15853992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
    Kudo M; Chung H; Osaki Y
    J Gastroenterol; 2003; 38(3):207-15. PubMed ID: 12673442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic accuracy of staging systems in patients with primary liver cancer undergoing transarterial chemoembolization.
    Zhuge Y; Zhang F; Qiu Y; Li Z; Zhang J
    Hepatogastroenterology; 2013 May; 60(123):481-8. PubMed ID: 23635440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area.
    Kang HY; Shin HD; Kim SB; Song IH
    Clin Res Hepatol Gastroenterol; 2012 Aug; 36(4):357-64. PubMed ID: 22326248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey.
    Huo TI; Lin HC; Hsia CY; Huang YH; Wu JC; Chiang JH; Chiou YY; Lui WY; Lee PC; Lee SD
    Dig Liver Dis; 2008 Nov; 40(11):882-9. PubMed ID: 18339595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Lee YH; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1581-8. PubMed ID: 22497632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of staging systems to predict survival in hepatocellular carcinoma.
    Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
    Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposal of the performance status combined Japan Integrated Staging system in hepatocellular carcinoma complicated with cirrhosis.
    Nishikawa H; Kita R; Kimura T; Endo M; Ohara Y; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Osaki Y
    Int J Oncol; 2015; 46(6):2371-9. PubMed ID: 25891119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.